POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
|
By LabMedica International staff writers Posted on 11 Feb 2025 |

Cardiovascular diseases continue to be the leading cause of death worldwide, accounting for over 19 million fatalities annually. Early detection of myocardial infarction (MI), commonly known as a heart attack, is essential for reducing mortality rates and improving patient outcomes. However, current high-sensitivity cardiac troponin I (cTnI) assays rely on large, costly laboratory equipment that requires trained personnel, limiting access to critical cardiac diagnostics, especially in low-resource settings where prompt clinical decision-making is vital. A new innovation, a deep learning-powered chemiluminescence vertical flow assay (CL-VFA), now brings laboratory-quality cTnI testing to a portable, cost-efficient point-of-care platform.
Researchers from the University of California, Los Angeles (UCLA, Los Angeles, CA, USA) have demonstrated how integrating chemiluminescence-based biosensing, high-sensitivity imaging via a portable reader, and AI-driven data analysis allows for rapid and highly sensitive cTnI quantification for MI detection in various clinical environments. This technology has the potential to provide fast, reliable cardiac diagnostics, particularly in areas with limited resources where advanced laboratory infrastructure is unavailable. In a study published in Small, the team introduced a novel point-of-care diagnostic platform that delivers high-sensitivity troponin testing in a compact, portable, and affordable design.
This platform integrates deep learning-based computational analysis with highly sensitive chemiluminescence biosensing, enabling the detection of cTnI at concentrations as low as 0.1-0.2 pg/mL and a broad dynamic range from less than 1 pg/mL to 100 ng/mL. These features outperform existing point-of-care devices and meet the clinical standards required for high-sensitivity troponin testing, which is crucial for early MI diagnosis and risk stratification. The sensor requires only 50 µL of serum and uses a streamlined workflow, allowing medical staff to perform tests with ease. It provides cTnI results in just 25 minutes, facilitating quick clinical decision-making. The computational sensor works in two primary phases: an immunoassay phase followed by washing and a chemiluminescence signal generation phase. During the immunoassay phase, a polymerized enzyme-based conjugate binds to cTnI in the serum. In the signal generation phase, a chemiluminescent material is activated by an enzymatic reaction, producing a light signal that is captured by a custom-designed portable reader. A deep learning algorithm then processes these images to determine cTnI concentrations in the serum sample.
The team validated the sensor platform rigorously using clinical serum samples. In a blinded validation study with patient samples, the sensor showed a strong correlation with an FDA-cleared laboratory analyzer, confirming its reliability, clinical accuracy, and potential for real-world diagnostic applications. The researchers plan to expand this paper-based sensor platform by integrating multiplexed detection of several cardiovascular biomarkers, allowing for comprehensive cardiac risk assessments in a single test. The high sensitivity, portability, simplicity, and affordability of this platform make it a viable alternative to traditional laboratory-based testing, bringing high-sensitivity cardiac diagnostics closer to patients. By democratizing access to fast, reliable biomarker testing, this innovation has the potential to enhance clinical decision-making, improve patient outcomes, and expand cardiac care globally, particularly in resource-constrained and decentralized healthcare settings.
“This technology represents a major step toward democratizing high-quality cardiac diagnostics,” said Dr. Aydogan Ozcan from UCLA who led the research team. “By combining AI-powered analysis, chemiluminescence biosensing, and portable high-sensitivity imaging, we can bridge the gap between central laboratory testing and real-time clinical decision-making in emergency rooms, rural clinics, and decentralized healthcare settings.”
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







